Patents by Inventor Rainer Kleemann

Rainer Kleemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PDE III inhibitors for treatment of asymptomatic heart failure
    Patent number: 11413285
    Abstract: A method for treating a patient suffering from ISACHC Classification Class I heart failure includes administering to the patient a therapeutically effective amount of pimobendan or a pharmaceutically acceptable salt thereof, where the administration results in a reduction in the size of the patient's heart.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: August 16, 2022
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • Use of pimobendan for the reduction of heart size in mammals suffering from heart failure
    Patent number: 10537588
    Abstract: A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: January 21, 2020
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann
  • PDE III INHIBITORS FOR TREATMENT OF ASYMPTOMATIC HEART FAILURE
    Publication number: 20190008862
    Abstract: A method for treating a patient suffering from ISACHC Classification Class I heart failure includes administering to the patient a therapeutically effective amount of pimobendan or a pharmaceutically acceptable salt thereof, where the administration results in a reduction in the size of the patient's heart.
    Type: Application
    Filed: September 11, 2018
    Publication date: January 10, 2019
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • PDE III inhibitors for treatment of asymptomatic heart failure
    Patent number: 10117869
    Abstract: Phosphodiesterase type III (PDE III) inhibitor or a “Ca2+-sensitizing agent” or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 6, 2018
    Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • USE OF PDE III INHIBITORS FOR THE REDUCTION OF HEART SIZE IN MAMMALS SUFFERING FROM HEART DISEASE
    Publication number: 20180185402
    Abstract: A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Application
    Filed: January 9, 2018
    Publication date: July 5, 2018
    Inventors: Juergen DAEMMGEN, Olaf JOENS, Rainer KLEEMANN
  • Use of pimobendan for the reduction of heart size in mammals suffering from heart failure
    Patent number: 9889148
    Abstract: A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: February 13, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann
  • Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
    Patent number: 9463199
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Grant
    Filed: March 23, 2005
    Date of Patent: October 11, 2016
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann
  • Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
    Patent number: 8980894
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having symptomatic or asymptomatic (occult) heart failure.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: March 17, 2015
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • USE OF PDE III INHIBITORS FOR THE REDUCTION OF HEART SIZE IN MAMMALS SUFFERING FROM HEART FAILURE
    Publication number: 20140155338
    Abstract: A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Juergen DAEMMGEN, Olaf JOENS, Rainer KLEEMANN
  • Use of PDE III Inhibitors For The Treatment of Asymptomatic (Occult) Heart Failure
    Publication number: 20100035889
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having symptomatic or asymptomatic (occult) heart failure.
    Type: Application
    Filed: June 11, 2009
    Publication date: February 11, 2010
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
    Publication number: 20090082282
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Application
    Filed: March 23, 2005
    Publication date: March 26, 2009
    Applicant: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann
  • METHOD FOR IMPROVING DIAGNOSTIC QUALITY IN ECHOCARDIOGRAPHY
    Publication number: 20070054838
    Abstract: The present invention provides a method for improving diagnostic quality in echocardiography, especially for patients having an elevated heart rate.
    Type: Application
    Filed: September 6, 2006
    Publication date: March 8, 2007
    Inventors: Marcus Stark, Rainer Kleemann, Juergen Daemmgen